# Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma

> **NCT07200102** · PHASE1 · RECRUITING · sponsor: **Washington University School of Medicine** · enrollment: 20 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Selinexor

## Key facts

- **NCT ID:** NCT07200102
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-17
- **Primary completion:** 2029-04-30
- **Final completion:** 2031-03-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07200102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07200102, "Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07200102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*